Last update 08 May 2025

VAP-1 x NCC x VMAT2

Basic Info

Related Targets
VAP-1NCCVMAT2

Related

1
Drugs associated with VAP-1 x NCC x VMAT2
Hydralazine hydrochloride/Hydrochlorothiazide/Reserpine
Target
NCC x VAP-1 x VMAT2
Mechanism
NCC inhibitors [+2]
Active Org.-
Originator Org.
Novartis Pharma AG
Active Indication-
Inactive Indication-
Drug Highest PhaseWithdrawn
First Approval Ctry. / Loc.
United States
First Approval Date11 Feb 1960
100 Clinical Results associated with VAP-1 x NCC x VMAT2
Login to view more data
100 Translational Medicine associated with VAP-1 x NCC x VMAT2
Login to view more data
0 Patents (Medical) associated with VAP-1 x NCC x VMAT2
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free